Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
M.BowieD.MeyersonJ
Biopharma companies face: Massive competition and potential market saturation with over 500 GLP-1-related clinical trials across 100+ indications Downward price pressure Highly restricted reimbursement and resistance to new indications Mechanism-based stratification can: Enrich clinical trials for responders (response biomarkers) Identify strong responder subgroups (complementary diagnostic) Differentiate competing assets Support development in new indications (biomarker-led indication switching) De-risk late-stage programs (clinical trial design) Past efforts to expand GLP-1s into new indications - such as the semaglutide Alzheimers trial - largely targeted broad patient groups defined by their clinical symptoms or diagnostic labels
SEMAGLUTIDE plan Tirzepatide/Glycine Tirzepatide is an innovative medication that targets weight management by combining the effects of two hormones, GLP-1 and GIP, which are involved in regulating appetite and glucose metabolism
The remaining patients usually stay at 1.7 mg long-term because of gastrointestinal side effects
US$ 22.36
US$ 29.13
US$ 23.88
US$ 24.63
US$ 25.16
